Anesthesia · Neuromuscular BlockadeRegulatory Approvalregulatorymid-term

Teva's Sugammadex Sodium Receives FDA Approval Status

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 12:30:42 PM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva's recent ANDA approval for Sugammadex Sodium is a significant development in the neuromuscular blockade market, indicating potential shifts in competitive dynamics. Pharma strategy teams should closely monitor this approval as it may influence pricing and market share among existing products. Regulatory context from FDA (FDA AP — SUGAMMADEX SODIUM (ORIG)) supports the near-term read. Assessment grounded in 15 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Teva's Sugammadex on market dynamics and consider strategies for differentiation. The strongest clinical anchor is Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain (ClinicalTrials.gov), sub-indication match (nmus rehab). In nmus rehab, 8 regulatory and 4 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval (Humanexa Signals) — sub-indication match (nmus rehab); entity match (sugammadex sodium). Secondary pressure from Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311). This approval status positions Teva to compete in the neuromuscular blockade market, potentially impacting existing products and pricing strategies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SUGAMMADEX SODIUM (ORIG) (FDA). Entity match (teva); Regulatory pathway relevance (nda). While the approval status is a positive step for Teva, the final approval and market entry timeline will be critical in determining the regulatory landscape and compliance requirements.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The entry of Teva's Sugammadex Sodium could disrupt current pricing strategies and market shares, necessitating adjustments from competitors to maintain their positions.
Portfolio teams should assess the impact of Teva's Sugammadex on market dynamics and consider strategies for differentiation.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval and market entry timeline for Sugammadex Sodium, as well as competitor responses.
Timeline shift beyond mid term would change urgency.
Outcome from Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval would change the regulatory/clinical read.
Outcome from Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311) would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source

Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain
ClinicalTrials.govhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Vibratory Anesthesia on Pain Following Corticosteroid Injections
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
FDA Grants Approval for Sugammadex Sodium ANDA219448 by Fresenius Kabi
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
FDA Grants Approval for Sugammadex Sodium under ANDA214368
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartislow relevance
Sponsor/company relevance (Novartis)
FDA document
View source

Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.
PubMedmedium relevance
Sub-indication match (nmus rehab)
FDA document
View source
Influence of Oliceridine on the Incidence of Postoperative Nausea and Vomiting in High-Risk Patients Stratified Using Apfel Score After General Anesthesia: A Prospective, Randomized Controlled Clinica
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Protocol for a cohort study: evaluating the effect of neoadjuvant immunochemotherapy on intraoperative remifentanil consumption during IoC2-guided anesthesia in elderly patients with esophageal cancer
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
Sugammadex Sodium

Commercial impact

medium

The entry of Teva's Sugammadex Sodium could disrupt current pricing strategies and market shares, necessitating adjustments from competitors to maintain their positions.

Regulatory impact

medium

While the approval status is a positive step for Teva, the final approval and market entry timeline will be critical in determining the regulatory landscape and compliance requirements.

What to watch

Monitor the final approval and market entry timeline for Sugammadex Sodium, as well as competitor responses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.